Highlights Strategies to Help Biotech Companies Minimize Market Access Failure
SOMERSET,N.J. / LONDON – November 10, 2014 – Alliance Life Sciences Consulting Group, a leading global life sciences consultancy and technology provider, announces that Sophie Murdoch, vice president, Consulting Services, will present “Transformational Market Access, Creating Success for Orphan Drug Launches,” which will cover the results of Alliance Life Sciences’ global online survey to identify the challenges and success factors that make or break orphan drug market access.
Murdoch will present at the World Orphan Drug Congress Europe 2014, Brussels, Belgium, November 12-14, 2014.Co-sponsored by Alliance Life Sciences’, the conference is Europe’s go-to event for orphan drug developers, patient groups and payers.
“Successfully commercializing a biotech is not an easy task,” says Murdoch. “Data has shown that of all theU.S. biotechnology companies founded since 1980 less than one percent are net positive. The industry cannot afford to make R&D mistakes in today’s environment with estimates of $4 billion to $5 billion being spent in R&D investment per successful drug commercialized.”
An overwhelming number of respondents to Alliance Life Sciences’ global survey stated that “meeting an unmet need”is the most important product driver for launch success.
“Recent studies showed that from the cancer and vaccine drugs in development, half were unable to complete clinical studies due to difficulties in enrolling patients,”Murdoch adds. Her presentation will discuss ways to ensure that a product launch is on track, and explore the critical need for Key Performance Indicators (KPIs) for enabling the industry to implement a successful market access strategy.